Serial medtech entrepreneur Dale Spencer died last week in Scottsdale, Ariz, according to the Medical Alley Association.
Spencer helped found more than a dozen medical device companies, including SciMed, eV3, EndoMetabolic Solutions, ConcepTx Medical and Anulex Technologies. He also served on the boards of Boston Scientific (NYSE:BSX), Micro Therapeutics, Northstar Neuroscience, Spine Wave, Vertis Neuroscience, Velocimed and CVRx.
“It is hard to even find the words to describe Dale’s impact on the entirety of medtech as it was so deep. From the companies that he created, the entrepreneurs he encouraged, the consistent advocacy of innovation, and the unwavering and relentless leadership that inspired so many to always do the right thing. But, I can put into words what he meant to all that knew him – he was a dearly loved friend and mentor with the heart of a lion. I speak for all when I say that our thoughts and prayers are with his wife Pat and his family,” close friend Stacy Sent, who co-founded eV3 with Spencer in 2000 said in a press release.
“Dale was a giant in the industry. When he joined SciMed it was a small surgical company struggling to survive. Dale transformed SciMed into a leader in the rapidly growing field of Interventional Cardiology. He drove Innovation, Quality and Speed as our competitive advantages. He built and continuously evolved the management team. Under his leadership the company grew 100 fold. He had a profound impact on thousands of employees and millions of patients and built a company, that to this day, as a major division of Boston Scientific, is a pillar of innovation in the Twin Cities. And his influence goes far beyond SciMed; Today, there are dozens of innovative companies that were created by people who learned entrepreneurship, innovation and management from Dale Spencer. He truly was a giant and will be sorely missed by all of us who knew and loved him,” Mike Berman, who worked with Spencer at Boston Scientific said in a prepared statement.
“At the time Frank joined NeuroMetrix, we had just obtained FDA clearance to market our Quell wearable pain relief technology directly to U.S. consumers. In the past two years, Frank and his team have rapidly built Quell into a new pain relief category with robust distribution through online, retail, and health care professional channels. This promotion recognizes Frank’s broad direction of the entire Quell effort, as well as his key role in Quell related operations. Moreover, Frank is leading our growing effort to develop strategic partnerships for the Quell brand and technology,” prez & CEO Dr. Shai Gozani said in a press release.
Endo International (NSDQ:ENDP) said this week it tapped current subsidiary Par Pharma ops veep Terrance Coughlin as its new exec veep & COO, effective as of November 1. Tony Pera was also tapped as prez of Par Pharma.
Coughlin joined Endo when the company bought Par Pharmaceutical Companies last year.
“I am excited and very pleased to add Terry and Tony to Endo’s Executive Leadership Team and to continue to strengthen the management of the company. Terry has worked closely with me over the past 25 years as a partner and collaborator, most recently leading the operations of Par Pharmaceutical. Tony brings experience and expertise that will be tremendously valuable in effectively managing our U.S. generics business. They are both seasoned and trusted executives who consistently deliver results and I have tremendous confidence in their ability to help drive operational excellence and growth for Endo,” prez & CEO Paul Campanelli said in a press release.